Safi Biotherapeutics, a biotech company producing stem-cell derived, human red blood cell (RBC) products for civilian and military transfusion needs, announced today it has been selected by the U.S. Army Medical Research and Development Command (USAMRDC) to receive a $3.5 million award from the U.S. Department of Defense (DoD) through the Medical Technology Enterprise Consortium (MTEC) Military Prototype Advancement Initiative (MPAI) for the optimization and standardization of enhanced cryo-storage capabilities unique to manufactured human red blood cells (mRBCs).